The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Atherosclerosis in ApoE-deficient mice progresses independently of the NLRP3 inflammasome
Open accessAbstract
The interleukin-1 (IL-1) family of cytokines has been implicated in the pathogenesis of atherosclerosis in previous studies. The NLRP3 inflammasome has recently emerged as a pivotal regulator of IL-1β maturation and secretion by macrophages. Little is currently known about a possible role for the NLRP3 inflammasome in atherosclerosis progression in vivo. We generated ApoE-/- Nlrp3-/-, ApoE-/- Asc-/- and ApoE-/- caspase-1-/- double-deficient mice, fed them a high-fat diet for 11 weeks and subsequently assessed atherosclerosis progression and plaque phenotype. No differences in atherosclerosis progression, infiltration of plaques by macrophages, nor plaque stability and phenotype across the genotypes studied were found. Our results demonstrate that the NLRP3 inflammasome is not critically implicated in atherosclerosis progression in the ApoE mouse model.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gout-associated uric acid crystals activate the NALP3 inflammasome
Martinon, F., Pétrilli, V., Mayor, A., Tardivel, A., & Tschopp, J. (2006) · Nature · doi:10.1038/nature04516 · Cited by 5,326
Self-citationNLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals
Duewell, P., Kono, H., Rayner, K. J., Sirois, C. M., Vladimer, G., Bauernfeind, F. G., Abela, G. S., Franchi, L., Nuñez, G., Schnurr, M., et al. (2010) · Nature · doi:10.1038/nature08938 · Cited by 4,026
The Inflammasomes: Guardians of the Body
Martinon, F., Mayor, A., & Tschopp, J. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132715 · Cited by 2,436
Self-citationAnti-inflammatory Agents: Present and Future
Dinarello, C. A. (2010) · Cell · doi:10.1016/j.cell.2010.02.043 · Cited by 1,095
Cited by
Inflammasomes: mechanism of action, role in disease, and therapeutics
Guo, H., Callaway, J. B., & Ting, J. P.-Y. (2015) · Nature Medicine · doi:10.1038/nm.3893 · Cited by 3,340
Macrophages in atherosclerosis: a dynamic balance
Moore, K. J., Sheedy, F. J., & Fisher, E. A. (2013) · Nature reviews. Immunology · doi:10.1038/nri3520 · Cited by 2,559
Inflammasomes in health and disease
Strowig, T., Henao-Mejia, J., Elinav, E., & Flavell, R. (2012) · Nature · doi:10.1038/nature10759 · Cited by 2,230
Atherosclerosis: current pathogenesis and therapeutic options
Weber, C., & Noels, H. (2011) · Nature Medicine · doi:10.1038/nm.2538 · Cited by 2,203
Cytokines in Inflammatory Disease
Kany, S., Vollrath, J. T., & Relja, B. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20236008 · Cited by 1,971
Cholesterol, inflammation and innate immunity.
Tall, A. R., & Yvan-Charvet, L. (2015) · Nature Reviews Immunology · doi:10.1038/nri3793 · Cited by 1,479
Inflammation and atherosclerosis: signaling pathways and therapeutic intervention
Kong, P., Cui, Z.-Y., Huang, X.-F., Zhang, D.-D., Guo, R.-J., & Han, M. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00955-7 · Cited by 1,183
NLRP3 inflammasome in cancer and metabolic diseases
Sharma, B. R., & Kanneganti, T.-D. (2021) · Nature Immunology · doi:10.1038/s41590-021-00886-5 · Cited by 1,097
Leukocyte Behavior in Atherosclerosis, Myocardial Infarction, and Heart Failure
Swirski, F. K., & Nahrendorf, M. (2013) · Science · doi:10.1126/science.1230719 · Cited by 1,086
NLRP3 Inflammasome and the IL-1 Pathway in Atherosclerosis
Grebe, A., Hoss, F., & Latz, E. (2018) · Circulation Research · doi:10.1161/circresaha.118.311362 · Cited by 926
Abderrazak, A., Syrovets, T., Couchie, D., El Hadri, K., Friguet, B., Simmet, T., & Rouis, M. (2015) · Redox Biology · doi:10.1016/j.redox.2015.01.008 · Cited by 732
Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease
Abbate, A., Toldo, S., Marchetti, C., Kron, J., Van Tassell, B. W., & Dinarello, C. A. (2020) · Circulation Research · doi:10.1161/circresaha.120.315937 · Cited by 730
How the immune system shapes atherosclerosis: roles of innate and adaptive immunity
Roy, P., Orecchioni, M., & Ley, K. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00584-1 · Cited by 565
Role of pyroptosis in cardiovascular disease
Zhaolin, Z., Guohua, L., Shiyuan, W., & Zuo, W. (2019) · Cell Proliferation · doi:10.1111/cpr.12563 · Cited by 493
Reactive oxygen species at the crossroads of inflammasome and inflammation
Harijith, A., Ebenezer, D. L., & Natarajan, V. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2014.00352 · Cited by 476
Molecular Biology of Atherosclerosis
Hopkins, P. N. (2013) · Physiological Reviews · doi:10.1152/physrev.00004.2012 · Cited by 459
NLRP3 inflammasome: Its regulation and involvement in atherosclerosis
Hoseini, Z., Sepahvand, F., Rashidi, B., Sahebkar, A., Masoudifar, A., & Mirzaei, H. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.25930 · Cited by 458
A role for the NLRP3 inflammasome in metabolic diseases—did Warburg miss inflammation?
Wen, H., Ting, J. P.-Y., & O'Neill, L. A. J. (2012) · Nature Immunology · doi:10.1038/ni.2228 · Cited by 457
NLRP3 inflammasomes link inflammation and metabolic disease
De Nardo, D., & Latz, E. (2011) · Trends in Immunology · doi:10.1016/j.it.2011.05.004 · Cited by 425
Koushki, K., Shahbaz, S. K., Mashayekhi, K., Sadeghi, M., Zayeri, Z. D., Taba, M. Y., Banach, M., Al-Rasadi, K., Johnston, T. P., & Sahebkar, A. (2021) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-020-08791-9 · Cited by 382
“Therefore, this study showed that the progression of atherosclerosis was independent of the activation of NLRP3-mediated inflammation [61].”
BackgroundMitochondria-associated membranes (MAMs) and inflammation
Missiroli, S., Patergnani, S., Caroccia, N., Pedriali, G., Perrone, M., Previati, M., Wieckowski, M. R., & Giorgi, C. (2018) · Cell Death & Disease · doi:10.1038/s41419-017-0027-2 · Cited by 379
de Zoete, M. R., Palm, N. W., Zhu, S., & Flavell, R. A. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a016287 · Cited by 379
Cholesterol Efflux Pathways Suppress Inflammasome Activation, NETosis, and Atherogenesis
Westerterp, M., Fotakis, P., Ouimet, M., Bochem, A. E., Zhang, H., Molusky, M. M., Wang, W., Abramowicz, S., la Bastide-van Gemert, S., Wang, N., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.032636 · Cited by 331
Targeting the NLRP3 inflammasome in cardiovascular diseases
Toldo, S., Mezzaroma, E., Buckley, L. F., Potere, N., Di Nisio, M., Biondi-Zoccai, G., Van Tassell, B. W., & Abbate, A. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.108053 · Cited by 328
Functions of NOD-Like Receptors in Human Diseases
Zhong, Y., Kinio, A., & Saleh, M. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00333 · Cited by 317
Freigang, S., Ampenberger, F., Weiss, A., Kanneganti, T.-D., Iwakura, Y., Hersberger, M., & Kopf, M. (2013) · Nature Immunology · doi:10.1038/ni.2704 · Cited by 307
NLRP3 Inflammasome Expression and Activation in Human Atherosclerosis
Paramel Varghese, G., Folkersen, L., Strawbridge, R. J., Halvorsen, B., Yndestad, A., Ranheim, T., Krohg‐Sørensen, K., Skjelland, M., Espevik, T., Aukrust, P., et al. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.115.003031 · Cited by 306
The Thioredoxin System as a Therapeutic Target in Human Health and Disease
Mahmood, D. F. D., Abderrazak, A., El Hadri, K., Simmet, T., & Rouis, M. (2013) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.4757 · Cited by 305
NLRP3 at the interface of metabolism and inflammation
Haneklaus, M., & O'Neill, L. A. J. (2015) · Immunological Reviews · doi:10.1111/imr.12285 · Cited by 294
Focus on the Role of NLRP3 Inflammasome in Diseases
Fusco, R., Siracusa, R., Genovese, T., Cuzzocrea, S., & Di Paola, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124223 · Cited by 290
Sensing damage by the NLRP3 inflammasome
Leemans, J. C., Cassel, S. L., & Sutterwala, F. S. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2011.01043.x · Cited by 281
The Influence of Innate and Adaptive Immune Responses on Atherosclerosis
Witztum, J. L., & Lichtman, A. H. (2014) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-020712-163936 · Cited by 277
Role of NLRP3 Inflammasomes in Atherosclerosis
Karasawa, T., & Takahashi, M. (2017) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv17001 · Cited by 276
Mechanisms That Regulate Macrophage Burden in Atherosclerosis
Randolph, G. J. (2014) · Circulation Research · doi:10.1161/circresaha.114.301174 · Cited by 265
Role of NLRP3 inflammasome in the pathogenesis of cardiovascular diseases
Liu, D., Zeng, X., Li, X., Mehta, J. L., & Wang, X. (2018) · Basic Research in Cardiology · doi:10.1007/s00395-017-0663-9 · Cited by 258
Zheng, Y., Humphry, M., Maguire, J. J., Bennett, M. R., & Clarke, M. C. H. (2013) · Immunity · doi:10.1016/j.immuni.2013.01.008 · Cited by 205
“, 2010), although recent work casts doubt on IL-1b’s role (Menu et al., 2011), suggesting that IL-1a could be the major ligand affecting atherosclerotic plaques.”
Xanthine Oxidase Inhibition by Febuxostat Attenuates Experimental Atherosclerosis in Mice
Nomura, J., Busso, N., Ives, A., Matsui, C., Tsujimoto, S., Shirakura, T., Tamura, M., Kobayashi, T., So, A., & Yamanaka, Y. (2014) · Scientific Reports · doi:10.1038/srep04554 · Cited by 181
Microdomains, Inflammation, and Atherosclerosis
Sorci-Thomas, M. G., & Thomas, M. J. (2016) · Circulation Research · doi:10.1161/circresaha.115.306246 · Cited by 165
Targeting inflammation to reduce cardiovascular disease risk: A realistic clinical prospect?
Welsh, P., Grassia, G., Botha, S., Sattar, N., & Maffia, P. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13818 · Cited by 164
Inflammasomes: sensors of metabolic stresses for vascular inflammation
Yang, X.-F. (2013) · Frontiers in Bioscience · doi:10.2741/4127 · Cited by 134
Wang, L., Chen, Y., Li, X., Zhang, Y., Gulbins, E., & Zhang, Y. (2016) · Oncotarget · doi:10.18632/oncotarget.12302 · Cited by 111
Monocytes and macrophages as protagonists in vascular complications of diabetes
Kanter, J. E., Hsu, C.-C., & Bornfeldt, K. E. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.00010 · Cited by 76
Metadata
- Authors
- Menu, P., Pellegrin, M., Aubert, J.-F., Bouzourene, K., Tardivel, A., Mazzolai, L., & Tschopp, J.
- Venue
- Cell Death & Disease
- Published
- 2011-03-31
- Volume
- 2
- Issue
- 3
- Pages
- e137-e137
- ISSN
- 2041-4889 (ISSN-L)
- OpenAlex
- W2026212701
- Cited by
- 251
- References
- 4
- FWCI
- 8.58
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.